Evidence map›Paper›PMID 36677735›Full record

ArticleMolecules (Basel, Switzerland)2023

Carbohydrate-Small Molecule Hybrids as Lead Compounds Targeting IL-6 Signaling.

Daniel C Schultz, Li Pan, Tiffany Wang, Conner Booker, Iram Hyder, Laura Hanold, Garret Rubin, Yousong Ding, Jiayuh Lin, Chenglong Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel C SchultzDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0002-7727-9148
Li PanDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Tiffany WangDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Conner BookerDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL 32610, USA.
Iram HyderDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL 32610, USA.
Laura HanoldDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0003-4492-9885
Garret RubinDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL 32610, USA.
Yousong DingDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL 32610, USA.
Jiayuh LinDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Chenglong LiDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL 32610, USA.

Funding

NIH Equipment Supplement to R35GM128742R35GM128742 · NIGMS · UNIVERSITY OF FLORIDA · PI Yousong Ding · 2018 to 2026
$3.4M
Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapyR01NS088437 · NINDS · UNIVERSITY OF FLORIDA · PI LI, CHENGLONG, YANG, YUHONG · 2015 to 2017
$1.3M
Acquisition of a Q Exactive HF Hybrid Quadrupole-OrbitrapS10OD021758 · OD · UNIVERSITY OF FLORIDA · PI BASSO, KARI B · 2017 to 2017
$600k
NIGMS NIH HHS R35 GM128742NIH HHS R01NS088437NIH HHS R35GM128742NIH HHS S10 OD021758NIH HHS S10 OD021758-01A1NINDS NIH HHS R01 NS088437
6 · The paper itself

Abstract

In the past 25 years, a number of efforts have been made toward the development of small molecule interleukin-6 (IL-6) signaling inhibitors, but none have been approved to date. Monosaccharides are a diverse class of bioactive compounds, but thus far have been unexplored as a scaffold for small molecule IL-6-signaling inhibitor design. Therefore, in this present communication, we combined a structure-based drug design approach with carbohydrate building blocks to design and synthesize novel IL-6-signaling inhibitors targeting glycoprotein 130 (gp130). Of this series of compounds,

Indexed as

Antineoplastic AgentsInterleukin-6CarbohydratesCell Line, TumorCell ProliferationDrug DesignDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureSignal TransductionStructure-Activity RelationshipAntineoplastic AgentsCarbohydratesInterleukin-6carbohydratedockingInterleukin-6structure-based drug design

Identifiers

PMID36677735
PMCPMC9861960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.